title: Lymphocytic variant hypereosinophilic syndromes.
abstract: A large body of evidence establishing the existence of an underlying T-cell disorder in a subset of patients fulfilling hypereosinophilic syndrome (HES) diagnostic criteria has accumulated over the past decade, resulting in the definition of a novel HES variant termed "lymphocytic" HES. Although end-organ complications of hypereosinophilia are generally benign, with predominant cutaneous manifestations, long-term prognosis is overshadowed by an increased risk of developing T-cell lymphoma, as a result of malignant transformation of aberrant T cells years after HES diagnosis. Therapeutic strategies should target pathogenic T cells in addition to eosinophils, but the practical implications remain largely unexplored.
authors.affiliation: Department of Internal Medicine, Erasme Hospital, Université Libre de Bruxelles, 808 Route de Lennik, B-1070 Brussels, Belgium. froufoss@ulb.ac.be
authors.forename: Florence
authors.initials: F
authors.lastname: Roufosse
authors.forename: Elie
authors.initials: E
authors.lastname: Cogan
authors.forename: Michel
authors.initials: M
authors.lastname: Goldman
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000503:physiopathology; D016176:T-Lymphocyte Subsets / Q000502:physiology*
chemical_list: D015703:Antigens, CD; D016207:Cytokines